Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events

ME Staff 8-k
-
0

Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Other Events
Item 8.01 Other Events

On November6, 2017, Esperion Therapeutics,Inc. issued a press release titled, “Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill.” A copy of the Press Release is filed herewith as Exhibit99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

ExhibitNo.

Description

99.1

Press Release dated November6, 2017.

***


Esperion Therapeutics, Inc. Exhibit
EX-99.1 2 a17-25221_2ex99d1.htm EX-99.1 Exhibit 99.1     Media Contact: Elliot Fox W2O Group 212.257.6724 [email protected]   Investor Contact: Mindy Lowe Esperion Therapeutics,…
To view the full exhibit click here

About Esperion Therapeutics,Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company’s lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.